Sol-Gel Technologies Ltd
Research Sol-Gel Technologies Ltd (SLGL) on Bullrun: market cap USD 267.55M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerSLGL
- ExchangeNASDAQ
- CountryIsrael
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 267.55M
- Financial periodQ1 2026
- RevenueUSD 108.00K
- Net income-USD 3.73M
Valuation Snapshot
latest market cap is USD 267.55M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 19.39M | -USD 6.13M | USD 275.00K | n/a | -2.19 | USD 11.03M | USD 991.00K | USD 22.81M |
| FY2024 | USD 11.54M | -USD 10.58M | -USD 13.89M | n/a | -3.79 | USD 19.49M | USD 1.31M | USD 28.85M |
| FY2023 | USD 1.55M | -USD 27.24M | -USD 17.86M | n/a | -10.01 | USD 7.51M | USD 1.65M | USD 38.64M |
| FY2022 | USD 3.88M | -USD 14.92M | -USD 9.66M | n/a | -0.65 | USD 12.45M | USD 1.07M | USD 42.21M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 267.55M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 117.39M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 25.91M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 30.78M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 105.47M | 217.1 | n/a | n/a |
| 2021 | 2021-12-31 | USD 171.14M | 569.2 | n/a | n/a |
About Sol-Gel Technologies Ltd
Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel, China, Switzerland, Canada, the United States and internationally. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Sol-Gel Technologies Ltd's market cap?
Sol-Gel Technologies Ltd's market capitalization is USD 267.55M.
What does Sol-Gel Technologies Ltd do?
Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel, China, Switzerland, Canada, the United States and internationally. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea.